Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma


In the past decade, several new antibody-based therapies – using either radiolabelled or unlabelled monoclonal antibodies – have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by inducing… (More)
DOI: 10.1007/s002590100570


5 Figures and Tables